Technical Analysis for IMMPF - Immupharma Plc

Grade Last Price % Change Price Change
grade F 0.14 16.67% 0.0200
IMMPF closed up 16.67 percent on Thursday, June 6, 2019, on 13 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical IMMPF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 16.67%
Wide Bands Range Expansion 16.67%
Gapped Up Strength 16.67%
Oversold Stochastic Weakness 16.67%
New 52 Week Closing Low Bearish 21.74%
Narrow Range Bar Range Contraction 21.74%

Older signals for IMMPF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists; and the development of peptides as glucagon antagonists to treat type I and type II diabetes; and a clinical development collaboration agreement with Incanthera Limited for Nucant cancer programme. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Medical Specialties Cancer Pharmaceutical Diabetes Peptide Hormones Autoimmunity Lupus Ii Diabetes Peptide Anti Diabetic Drugs Treatment Of Lupus
Is IMMPF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 2.68
52 Week Low 0.115
Average Volume 12,111
200-Day Moving Average 0.0
50-Day Moving Average 1.545
20-Day Moving Average 0.665
10-Day Moving Average 0.1465
Average True Range 0.1249
ADX 37.32
+DI 26.5633
-DI 67.9444
Chandelier Exit (Long, 3 ATRs ) 2.1253
Chandelier Exit (Short, 3 ATRs ) 0.4897
Upper Bollinger Band 2.2769
Lower Bollinger Band -0.9469
Percent B (%b) 0.34
BandWidth 484.781955
MACD Line -0.4538
MACD Signal Line -0.4496
MACD Histogram -0.0042
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1400
Resistance 3 (R3) 0.1400 0.1400 0.1400
Resistance 2 (R2) 0.1400 0.1400 0.1400 0.1400
Resistance 1 (R1) 0.1400 0.1400 0.1400 0.1400 0.1400
Pivot Point 0.1400 0.1400 0.1400 0.1400 0.1400
Support 1 (S1) 0.1400 0.1400 0.1400 0.1400 0.1400
Support 2 (S2) 0.1400 0.1400 0.1400 0.1400
Support 3 (S3) 0.1400 0.1400 0.1400
Support 4 (S4) 0.1400